ClinicalTrials.gg
Not yet recruitingNCT06945445Updated Apr 25, 2025

Study of SLN12140 in Healthy Adult Participants

A Phase 1 interventional study of SLN12140 and Placebo in Healthy Volunteer, sponsored by Linno Pharmaceuticals, Inc.. Not yet recruiting at 3 sites in China. Open to participants aged 18 Days to 65 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-25.

Sponsored by Linno Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Days to 65 Days
Sex
All
01

Study summary

A randomized, double-blind, placebo-controlled phase I clinical study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SLN12140 in healthy participants with single subcutaneous/intravenous dose escalation and multiple subcutaneous administrations

Read the detailed description

This study will include up to 7 different dosing cohorts, with each cohort consisting of 2 groups (SLN12140 group, placebo group). Participants will be randomly assigned in a 3:1 ratio to each of these 2 groups, respectively, within all 7 cohorts, to receive either a single or multiple doses of ALXN1820 SC, a single dose of ALXN1820 IV, or a single or multiple doses of placebo.

The study will be conducted in healthy adult participants .

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Linno Pharmaceuticals, Inc. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Days to 65 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in clinical trials and sign written , and be able to complete the whole trial process according to the requirements of the trial.
  2. Persons of any gender, aged between 18 and 65 years old (including the boundary value).
  3. Weight: male ≥50kg , female ≥45kg ; (BMI) within the range of 19.0 to 28.0 kg/m2 (including cut-off values).
  4. Those whose medical history, physical examination, vital signs examination, examination, laboratory examination indicators, and anteroposterior chest X-ray are all normal or abnormal but non as judged by the investigator.
  5. Participant has received the following vaccines:

    • Meningococcal polysaccharide vaccine ACYW135 (MPV-ACYW) or meningococcal polysaccharide conjugate vaccine ACYW135 (MPCV-ACYW), given at least two weeks before the first dose and no earlier than within 2 years before the first dose;
    • 13-valent pneumococcal conjugate vaccine (PCV13) or 23-valent pneumococcal polysaccharide vaccine (PPV23) at least two weeks before the first dose, and no earlier than 8 weeks before the first dose of PCV13 and no earlier than 4 years before the first dose of PPV23.
  6. Normal or abnormal but no clinical significance with ECG results ,such as interval ≤450ms (males) and QTcF interval ≤470ms (females); PR interval ≤ 209 ms; The QRS interval ≤ 120 ms.
  7. During the study period and within 3 months after the last dose of the study, there is no childcare plan and can take highly effective measures and cannot donate sperm or eggs.

Exclusion criteria

Exclusion Criteria:

  1. Have cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic or nervous system diseases that affect the absorption, distribution, metabolism or elimination of drugs; or those with disease or medical history that may interfere with the interpretation of study data.
  2. Those who have any previous history of Neisseria meningitidis.
  3. Those who have a positive skin test for penicillin. Those who have known allergies or to penicillin or any vaccine ingredients, or who are known to be allergic to the trial drug and any of its ingredients or related preparations, or who have any history of allergies to food, drugs, or allergic diseases or allergies.
  4. Those who have or are suspected of having any active viral, bacterial, fungal or parasitic infection, or receiving any anti-infective treatment within 1 month prior to screening.
  5. Those with a history of recurrent or chronic infection (such as recurrent upper respiratory tract infection, diarrhea, etc.) within 3 months before screening.
  6. Within 1 month prior to screening, have received a , or plan to receive a vaccine during the study (except for vaccinations required for the study).
  7. Received drugs that may interact with penicillin V potassium within 7 days or 5 elimination half-lives (whichever is longer) prior to dosing.
  8. Those who have any of the following abnormalities in laboratory tests during the screening stage:

    • (ALT) or aspartate aminotransferase (AST) or alkaline phosphatase (ALP) exceeds the normal range;
    • Total (TBIL) ≥ 1.5 times the (ULN);
    • eGRF ( formula) \<90 mL/min/1.73m2;
    • \< lower limit of normal range (LLN).
  9. At the time of screening, the results of complement C3 and C4 examinations are lower than the lower limit of the normal reference value range and the abnormalities judged by the investigator to be .
  10. , or suffering from at least one of the following underlying diseases:

    • Anatomical or functional asplenia (including sickle cell disease);
    • Congenital complement deficiency (complement factor P deficiency, complement factor B deficiency, or complement factor D deficiency);
    • Acquired complement deficiency;
    • (HIV) infection or acquired immunodeficiency syndrome.
  11. Those who are positive for surface antigen (HBsAg), virus (HCV) antibody, Treponema pallidum antibody (TPPA) and HIV antibody.
  12. Those who have donated or lost more than 400 mL of blood or have a history of blood transfusion within 30 days before screening or Day-1.
  13. Within 90 days prior to screening or Day-1, the participant has received drug administration, or is currently participating in another clinical study (including the follow-up period).
  14. Participants who have used any prescription or over-the-counter medications, any vitamin products, or herbal remedies within 7 days prior to dosing.
  15. Those who have any history of intolerance to subcutaneous injection or related injection site scars (surgery, burns, tattoos, etc.) that would affect the evaluation of injectable drug administration.
  16. Those who are unwilling or unable to use antibiotic prophylaxis specified in the protocol.
  17. A person who falls under any of the following conditions:

    • Professionals at high risk of exposure to meningococcal disease
    • Research, industrial, or clinical laboratory personnel who are at risk of exposure to meningococcals
    • Planned travel to areas where meningococcal is endemic (e.g., India, sub-Saharan Africa, Saudi Arabia) during the study period, or have traveled to these areas within 6 months of the day prior to the start of the study.
  18. A current or former drug abuser.
  19. Day-1 Positive Drug Abuse Screen.
  20. Those who have been an alcoholic within the current period of 3 months or in the past (drinking more than 14 standard units per week. 1 standard unit contains 14 g of alcohol, e.g. 360 mL of beer or 45 mL of spirits with 40% alcohol or 150 mL of wine).
  21. Those who have a positive Day-1 alcohol breath test (>0.0mg/100mL).
  22. Use of more than 10 cigarettes (or equivalent nicotine-containing products) per week or more than 5 cigarettes (or equivalent nicotine-containing products) per day within 4 weeks prior to screening.
  23. Day-1 urine cortinine test positive.
  24. Those who have taken a special diet (including dragon fruit, mango, grapefruit, etc.) within 24 hours before administration or have strenuous exercise, or other factors that affect the absorption, distribution, metabolism, and excretion of drugs.
  25. Pregnant or lactating female participants or those with a positive pregnancy test.
  26. Those who are unable to receive venipuncture, or faint blood and faint needles.
  27. Those who are considered by the investigator to have other factors that are not suitable for participating in the trial.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    SLN12140

    a single dose of SLN12140 by subcutaneous (sc) injection:50mg ; a single dose of SLN12140 by subcutaneous (sc) injection:150mg; a single dose of SLN12140 by subcutaneous (sc) injection:450mg ; a single dose of SLN12140 by intravenous(IV) injection:450mg ; a single dose of SLN12140 by subcutaneous (sc) injection:900mg ; a single dose of SLN12140 by subcutaneous (sc) injection:1500mg\~1800mg

    Drug: SLN12140

  • Placebo comparator
    Placebo

    Placebo (SLN12140 formulation buffer) will be provided as an injectable solution without active ingredient.

    Other: Placebo

Interventions

  • SLN12140 for sc injection or IV infusion

  • OtherPlacebo

    Placebo for sc injection or IV infusion

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of SLN12140

    Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs)

    Time frame: 36 days

Secondary outcomes

  1. Pharmacokinetics-Cmax

    Maximum Observed Plasma Concentration (Cmax)

    Time frame: 36 days

  2. Pharmacokinetics-Tmax

    Time at which the maximum plasma concentration (Cmax) occurs

    Time frame: 36 days

  3. Pharmacokinetics-AUClast

    Area under the plasma concentration-time curve from dosing (time zero) to the time of the last measured concentration

    Time frame: 36 days

  4. Pharmacokinetics-AUCinf

    Area Under the Plasma Concentration Versus Time Curve from Zero Extrapolated to Infinity (AUCinf)

    Time frame: 36 days

  5. Pharmacokinetics-t1/2

    Terminal Elimination Half-Life (t1/2)

    Time frame: 36 days

  6. Pharmacokinetics-Vd/F

    Volume of Distribution (Vd/F)

    Time frame: 36 days

  7. Pharmacokinetics-CL/F

    Total Body Clearance

    Time frame: 36 days

  8. Pharmacokinetics-λz

    Elimination rate constant (λz)

    Time frame: 36 days

  9. Pharmacokinetics-MRT

    Mean retention time (MRT)

    Time frame: 36 days

  10. Pharmacokinetics-AUC 0-t, sc/AUC 0-t,iv;AUC 0-inf, sc/ AUC 0-inf,iv

    Subcutaneous bioavailability-(AUC 0-t, sc/AUC 0-t,iv;AUC 0-inf, sc/ AUC 0-inf,iv)

    Time frame: 36 days

  11. Pharmacodynamics-CFP

    Change From Baseline in Total and Free Complement factor P (CFP)

    Time frame: 36 days

  12. Pharmacodynamics-AP activity

    Change From Baseline in alternative pathway activity (AP)

    Time frame: 36 days

  13. Pharmacodynamics-CP, LP Activity

    Change From Baseline in Classical pathway and Lectin Pathway (CP, LP)

    Time frame: 36 days

  14. Immunogenicity-ADA, Nab

    Anti-drug antibody positive rate (ADA); ADA titer and Neutralizing antibody rate (Nab)

    Time frame: 36 days

07

Study locations

3 sites
  • Huashan Hospital
    Shanghai, Shanghai 200040, China
  • Phase I center of Fudan University Huashan Hospital
    Shanghai, Shanghai 200040, China
    • Jing Zhang, Doctor of Pharmacy · Contactzhangj_fudan@163.com · 0086+13816357098
    • Xiaojie Wu, Doctor of Pharmacy · Contactmaomao_xj@163.com · 0086+13524686330
    • Jing Zhang, Doctor of Pharmacy · Principal investigator
    • Xiaojie Wu, Doctor of Pharmacy · Principal investigator
  • Huashan Hospital
    Shanghai, Shanghai, China
    • Jing Zhang, Principal Investigator · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for May 2026, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2025
First posted
Apr 25, 2025
StartEst.
Apr 2025
Primary completionEst.
May 2026
CompletionEst.
Jun 2026
Last update
Apr 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06945445
Lead sponsor
Linno Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Apr 25, 2025
Start date
Apr 2025 (estimated)
Primary completion
May 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Apr 25, 2025

Study contacts

Jing Zhang, Doctor of Pharmacy
Contact
zhangj_fudan@163.com
0086+13816357098
Xiaojie Wu, Doctor of Pharmacy
Contact
maomao_xj@163.com
0086+13524686330
Jing Zhang, Doctor of Pharmacy
principal investigator · Huashan Hospital
Xiaojie Wu, Doctor of Pharmacy
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SLN12140

Start the discussion